Published: 4 June 2026
Publications
Recent approvals: New active ingredients or new indications
Published: 4 June 2026
Prescriber Update 47(2): 28
June 2026
New active ingredients
Table 1 shows recent approval of medicines with new active ingredients gazetted during the period 23 January to 23 April 2026.
Table 1: Recent approvals of medicines with new active ingredients
| Medicine | New active ingredient | Dose form: Strength(s) | Therapeutic area |
|---|---|---|---|
| Andembry | Garadacimab | Solution for injection: 200mg | Prevention of hereditary angioedema |
| Blenrep | Belantamab mafodotin | Powder for injection: 70mg, 100mg |
Multiple myeloma |
New indications
Table 2 shows approved medicines with new indications for additional therapeutic areas gazetted during the period 23 January to 23 April 2026.
Table 2: Approved medicines with new indications for additional therapeutic areas
| Medicine (active ingredient) | Dose form: Strength(s) | New therapeutic area |
|---|---|---|
| Yervoy (ipilimumab) | Concentrate for injection: 50mg/10mL, 200mg/40mL | Colorectal cancer Hepatocellular carcinoma |
| Winglore (ipilimumab) | Concentrate for injection: 50mg/10mL, 200mg/40mL | Colorectal cancer Hepatocellular carcinomaa |
| Opdivo (nivolumab) | Concentrate for infusion: 40mg/4mL, 100mg/10mL | Colorectal cancer |
| Ozempic (semaglutide) | Solution for injection: 2mg/1.5mL, 4mg/3mL | Chronic kidney diseasea |
| Tezspire (tezepelumab) | Prefilled syringe for injection: 210mg Prefilled pen for injection: 210mg |
Chronic rhinosinusitis with nasal polyps |
| Tevimbra (tislelizumab) | Concentrate for injection: 100mg/10mL | Gastric or gastro-oesophageal junction adenocarcinoma |
a. In adults with type 2 diabetes.
More information
See the Medsafe website for:
